

TRANSITIONS

A NEWSLETTER FOR EQUITY HOLDERS OF TRT

Vol. 40 / March 2018
Woodstock, GA

AUA

It is that time of year. TRT will be attending the 2018 American Urological Associations annual meeting in beautiful San Francisco, CA May 18 - 21. There will be 12,000 plus attendees from around the world who want to see what the buzz is about surrounding our TRT Softwave therapy. There will be numerous presentations and poster sessions discussing the potential benefits of using shockwave therapy on various urological indications such as ED, CPPS, and Peyronies disease. The future looks promising. Come see us in booth 6675. We hope to see you there!



ISMST

Kia ora tatou (Hello everyone). TRT will be attending this year's ISMST congress in Auckland, New Zealand. The meeting will be held April 11 – 14, 2018. The ISMST includes the world's leading experts in the field of regenerative shockwave science and medicine. The message presented at this meeting will be "The Age of Regenerative-Shockwave Medicine." This year's congress will include multiple discussions on how ESWT can and does benefit individuals with Urologic indications. TRT's research team is considered the "top of the class" when it comes to ESWT research. Our team has more first and second place finishes than any other shockwave provider on research presentations. Cash in your sky miles and come see us in beautiful New Zealand.

TRT is excited to announce that it is launching a study with one of the largest and respected Urology groups in the United States. This study will include twenty patients over a six week period. We will be evaluating the effects Softwaves have on various Urologic indications that may benefit from improved vascularity. Preliminary results have been promising. We will provide an update when the study concludes. We will be able to announce who our strategic partner is at this time as well. Keep your fingers crossed.

Contact Us


Tissue Regeneration Technologies, LLC

251 Heritage Walk
Woodstock, GA 30188
(404) 402-6844
Email: info@trtllc.com
Website: www.trtllc.com

Vol. 40 / March 2018

Physiatry

TRT displayed the OrthoGold 100 at the 2018 Association of Academic Physiatrists Annual Meeting held in Atlanta in February. Attended by more than 1,000 Physiatrists, there was great interest in the use of SoftWaves for the treatment of Pain and Musculoskeletal Conditions. TRT is enthusiastic at the market opportunities this rapidly growing specialty of physicians presents.



Sports Medicine



Major League Baseball

TRT is making waves in Major League Baseball. The Cleveland Indians have implemented the OrthoGold 100 into their organization and are experiencing outstanding results. The Chicago Cubs are the most recent MLB team to partner with TRT and purchase the device. This was following the stellar outcomes reported by the Cubs Medical Staff during the evaluation. We look forward to working with the Cubs moving forward and developing similar relationships with additional professional franchises.

National Basketball Association

TRT is enthusiastic about the tremendous potential the invitation to the NBA Trainers Association meeting in Chicago presents. This meeting is attended by all the NBA Trainers as well as the home of the Rookie Combine. This is a fantastic opportunity to introduce our Technology to the entire NBA.

National Football League

TRT has been invited to demonstrate the OrthoGold 100 at the Star, a Baylor Scott and White Facility in Frisco, TX. This world-class sports and medical complex is the home of the Dallas Cowboys. The Star exclusively features State-of-the-Art Technology and the OrthoGold would provide an innovative approach to the practice of Musculoskeletal Medicine.

It is tax time already. Your TRT K1s have been sent. If you have not received yours by March 19th please contact Daniel Kirkland at dkirkland@trtlc.com. We can re-send or email them to you. Thank you for your patience.

This newsletter is not an offer to sell or solicitation of an offer to buy TRT securities. Investment decisions should be based on the risks and disclosures presented in TRT's Confidential Memorandum. This newsletter contains forward looking statements within the meaning of the federal securities laws. Forward looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements.